{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:53:42Z","timestamp":1770825222325,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,7,23]],"date-time":"2009-07-23T00:00:00Z","timestamp":1248307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Otolaryngology"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:p><jats:bold>Objectives:\u2002<\/jats:bold> This study aimed to evaluate the response of refractory Wegener\u2019s granulomatosis affecting the ear, nose and throat and granulomatous eye disease to B\u2010cell depletion with rituximab.<\/jats:p><jats:p><jats:bold>Design:\u2002<\/jats:bold> A retrospective case note review.<\/jats:p><jats:p><jats:bold>Setting:\u2002<\/jats:bold> Tertiary Centre.<\/jats:p><jats:p><jats:bold>Participants:\u2002<\/jats:bold> All patients who received rituximab for refractory Wegener\u2019s granulomatosis affecting the head and neck were included.<\/jats:p><jats:p><jats:bold>Main outcome measures:\u2002<\/jats:bold> Demographic and follow\u2010up data at five time points were recorded. Response was measured using change in the Birmingham Vasculitis Activity Score and prednisolone dose. Secondary outcomes included changes in additional immunomodulators and anti\u2010neutrophil cytoplasm antibodies serology. Adverse events were recorded for the duration of follow\u2010up.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Thirty\u2010four patients were included in the analysis. The median age was 47, the male to female ratio was 3\u2003:\u20032 and the overall median follow\u2010up was 25.5\u2003months. At six months, nine (26%) patients had a partial response, twenty\u2010one (62%) were in remission and four (12%) did not respond. All four non\u2010responders went into remission after a second course of rituximab. Total Birmingham Vasculitis Assessment score decreased after rituximab at all time points (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001). Four of five patients with retro\u2010orbital involvement responded well to treatment. Two patients were considered secondary failures requiring alternative therapy after an initial response. Adverse events included four major chest infections, two cancers and six infusion reactions.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Our cohort derived considerable benefit from rituximab permitting a reduction in immunosuppressive exposure and prednisolone dose with few major adverse effects. There was an 80% (4\/5) response in patients with retro\u2010orbital granulomas. The effect of rituximab was most noticeable in the first 6\u2003months (88% response).<\/jats:p>","DOI":"10.1111\/j.1749-4486.2009.01968.x","type":"journal-article","created":{"date-parts":[[2009,7,23]],"date-time":"2009-07-23T11:14:33Z","timestamp":1248347673000},"page":"328-335","source":"Crossref","is-referenced-by-count":79,"title":["B\u2010cell depletion with rituximab for refractory head and neck Wegener\u2019s granulomatosis: a cohort study"],"prefix":"10.1111","volume":"34","author":[{"given":"M.","family":"Martinez Del Pero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.B.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sivasothy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Jani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,7,23]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054593"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)63594-5"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-6-488"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666090-00004"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21142"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020286"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041884"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868060-00003"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.081661"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5394.1998.006003195.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-007-8026-1"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20718"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200507-1144OC"},{"key":"e_1_2_8_15_2","first-page":"2017","article-title":"Efficacy of rituximab in limited Wegener\u2019s granulomatosis with refractory granulomatous manifestations","volume":"35","author":"Seo P.","year":"2008","journal-title":"J. Rheumatol."},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.044420"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.173.7.815a"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062711"},{"key":"e_1_2_8_19_2","first-page":"315","article-title":"Wegener\u2019s granulomatosis: studies in eighteen patients and a review of the literature. 1973","volume":"73","author":"Fauci A.S.","year":"1994","journal-title":"Medicine"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22046"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/02813430510015269"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.075689"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel098"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl573"}],"container-title":["Clinical Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-4486.2009.01968.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-4486.2009.01968.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T23:43:51Z","timestamp":1697413431000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-4486.2009.01968.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,23]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1749-4486.2009.01968.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-4486.2009.01968.x","archive":["Portico"],"relation":{},"ISSN":["1749-4478","1749-4486"],"issn-type":[{"value":"1749-4478","type":"print"},{"value":"1749-4486","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,23]]}}}